

**ASX Announcement | 10 October 2023
Vioneering Technologies (ASX:VTI)**

Updated timetable for capital raising

Vioneering Technologies, Inc. (ASX: VTI) ('Vioneering' or 'the Company'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, advises that the timetable in respect of Rights Offering announced today has been updated. The updated timetable is as follows:

Event	Date
"Ex" Date for Rights Offering	Friday, 13 October 2023
Record Date to determine entitlement to participate in the Rights Offering	7:00pm, Monday, 16 October 2023
Dispatch Offer Booklet and personalised entitlement and acceptance forms to Eligible Holders	Thursday, 19 October 2023
Rights Offering opens	9:00am, Thursday, 19 October 2023
Special meeting of stockholders	8:00am, Thursday, 26 October 2023
Rights Offering closes	5:00pm, Monday, 30 October 2023
Announce results to ASX	By Monday, 6 November 2023
Issue of CDIs under Rights Offering and Placement, conversion of Convertible Notes to CDIs	Monday, 6 November 2023
CDIs under Rights Offering commence trading on ASX on a normal basis	Tuesday, 7 November 2023
Dispatch of holding statements	Thursday, 9 November 2023

Note: The timetable above is indicative only and may be varied subject to the Listing Rules. All times are references to Sydney time.

Vioneering reserves the right to amend any or all of these dates and times, subject to the *Corporations Act 2001* (Cth), the Listing Rules and other applicable laws and regulations. Vioneering reserves the right to extend the closing date of the Rights Offering, to accept late applications (either generally or in particular cases) and to withdraw the Rights Offering without prior notice. Any extension of the closing date may have a consequential impact on the date that new CDIs are issued. Applicants are encouraged to submit their acceptance forms as soon as possible after the Rights Offering opens.

Enquiries

Eligible Holders will be sent further details about the Rights Offering in an Offer Booklet. Eligible Holders should read the Offer Booklet carefully before making any investment decision regarding the Rights Offering.

For further information regarding the Rights Offering, please call the Rights Offering Information Line on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.00pm (AEDT) on Business Days during the offer period for the Rights Offering.

Ends

This release was authorized by the COO and CFO, Brian Lane.

For more information, please contact:

Company	Investor and media relations
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtivision.com or call +1 844-884-5367, ext. 104.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.